Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Real-world Study Aimed At Evaluating the Efficacy and Safety of 240 Mg/d Furmonertinib Combined with Bevacizumab and Pemetrexed in the Treatment of Advanced NSCLC with EGFRm and Leptomeningeal Metastasis.

NCT06643000 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT06643000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06643000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Real-world Study Aimed At Evaluating the Efficacy and Safety of 240 Mg/d Furmonertinib Combined with Bevacizumab and Pemetrexed in the Treatment of Advanced NSCLC with EGFRm and Leptomeningeal Metastasis.
Lead sponsor
Henan Cancer Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
December 20, 2024
Completion date
May 30, 2025
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

egfr gene mutation, leptomeningeal metastasis, non-small cell lung cancer